Outcomes after trimodality therapy for esophageal cancer: The impact of histology on failure patterns

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 3, 2011, Pages 259-264

  Koshy, Matthew ^a   Greenwald, Bruce D ^a   Hausner, Petr ^a   Krasna, Mark J ^a   Horiba, Naomi ^a   Battafarano, Richard J ^b   Burrows, Whitney ^b   Suntharalingam, Mohan ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b St Joseph Cancer Institute   (United States)

Author keywords

esophageal; histology; neoadjuvant; pathologic response; trimodality

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; DISEASE COURSE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RADIATION DOSE FRACTIONATION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79958257600     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181e841ce     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96. (Pubitemid 351521864)
2. Schneider BJ, Urba SG. Preoperative chemoradiation for the treatment of locoregional esophageal cancer: the standard of care? Semin Radiat Oncol. 2007;17:45-52. (Pubitemid 44918356)
3. Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 2003;185:538-543. (Pubitemid 36627845)
4. Fiorica F, Di Bona D, Schepis F, et al. Preoperative chemoradiotherapy for esophageal cancer: a systematic review and meta-analysis. Gut. 2004;53:925-930. (Pubitemid 38824146)
5. Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in esophageal carcinoma: a metaanalysis. Lancet Oncol. 2007;8:226-234. (Pubitemid 46291702)
6. Rizk NP, Seshan VE, Bains MS, et al. Prognostic factors after combined modality treatment of squamous cell carcinoma of the esophagus. J Thorac Oncol. 2007;2:1117-1123. (Pubitemid 350307906)
7. Rohatgi PR, Swisher SG, Correa AM, et al. Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer. 2006;106:552-558. (Pubitemid 43157617)
8. Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19:305-313. (Pubitemid 32112841)
9. Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the esophagus: A randomised controlled phase III trial. Lancet Oncol. 2005;6:659-668. (Pubitemid 41222756)
10. Le Prise E, Etienne PL, Meunier B, et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer. 1994;73:1779-1784. (Pubitemid 24101950)
11. Rohatgi P, Swisher SG, Correa AM, et al. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer. 2005; 104:2365-2372. (Pubitemid 41691557)
12. Greene FL, American Joint Committee on Cancer, American Cancer Society. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002.
13. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73:2680-2686. (Pubitemid 24166250)
14. Greer SE, Goodney PP, Sutton JE, et al. Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery. 2005;137:172-177. (Pubitemid 40174424)
15. Nomura H, Sou S, Tanimoto H, et al. Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology. 2004;39:1213-1219. (Pubitemid 38569042)
16. Graham AJ, Shrive FM, Ghali WA, et al. Defining the optimal treatment of locally advanced esophageal cancer: a systematic review and decision analysis. Ann Thorac Surg. 2007;83:1257-1264. (Pubitemid 46440778)
17. De Vita F, Di Martino N, Orditura M, et al. Preoperative chemoradiotherapy for squamous cell carcinoma and adenocarcinoma of the esophagus: a phase II study. Chest. 2002;122:1302-1308. (Pubitemid 35339545)
18. Bates BA, Detterbeck FC, Bernard SA, et al. Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. J Clin Oncol. 1996;14:156-163. (Pubitemid 26020008)
19. Stahl M, Wilke H, Fink U, et al. Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer. Interim analysis of a phase II trial. J Clin Oncol. 1996;14:829-837. (Pubitemid 26085528)
20. Chirieac LR, Swisher SG, Ajani JA, et al. Post-therapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103:1347-1355. (Pubitemid 40410728)
21. Forastiere AA, Heitmiller RF, Kleinberg L. Multimodality therapy for esophageal cancer. Chest. 1997;112:195S-200S. (Pubitemid 27441079)
22. Rizk NP, Venkatraman E, Bains MS, et al. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol. 2007;25:507-512. (Pubitemid 350002956)
23. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996; 335:462-467. (Pubitemid 26269945)
24. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26: 1086-1092.
25. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23:2310-2317. (Pubitemid 46218723)
26. Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25:1160-1168. (Pubitemid 46640561)
27. Suntharalingam M, Haas ML, Sonett JR, et al. Accurate lymph node assessment prior to trimodality therapy for esophageal carcinoma. Cancer J. 2001;7:509-515.
28. Krasna MJ, Jiao X, Mao YS, et al. Thoracoscopy/laparoscopy in the staging of esophageal cancer: Maryland experience. Surg Laparosc Endosc Percutan Tech. 2002;12:213-218. (Pubitemid 36401733)
29. Wu DL, Sui FY, Jiang XM, et al. Methylation in esophageal carcinogenesis. World J Gastroenterol. 2006;12:6933-6940.
30. Greenawalt DM, Duong C, Smyth GK, et al. Gene expression profiling of esophageal cancer: comparative analysis of Barrett's esophagus, adenocarcinoma, and squamous cell carcinoma. Int J Cancer. 2007;120:1914-1921. (Pubitemid 46418367)
31. Kleinberg L, Forastiere AA. Chemoradiation in the management of esophageal cancer. J Clin Oncol. 2007;25:4110-4117. (Pubitemid 47492955)
32. Geh JI, Bond SJ, Bentzen SM, et al. Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in esophageal cancer: evidence of a radiation and chemotherapy dose response. Radiother Oncol. 2006;78:236-244.